F2G Ltd Announces the Appointment of Michael R. Hodges, M.D. to the Board of Directors
F2G Limited announced the appointment of Dr Michael R. Hodges to the Company’s Board of Directors.
Michael R Hodges, M.D., BSc., MRCP (UK) has 20 years of biopharmaceutical development experience and has worked in both biotechnology and large pharmaceutical companies. Whilst at Pfizer Inc. Dr. Hodges was the development team leader for Vfend™, as well as working on the Eraxis™ and Diflucan™ antifungal programs. In addition Dr. Hodges worked on the Zithromax™ and HIV portfolio development programs.
Prior to joining industry at Pfizer Inc. in 1990, Dr. Hodges practiced internal medicine in London, UK. 1989-90 he held an appointment through the Medical Research Council (UK), at St Thomas’ Hospital, London, HIV clinical trials unit. From 1992 to 2001 he held honoree positions with East Kent Hospitals University NHS Foundation Trust.
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.